Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A roundup of widely followed U.S. equities pointed to a market pulling toward fresh highs even as individual results, including notable moves tied to SpaceX and major semiconductor players, reshaped near-term sentiment.
THE APEX TIMES
THE APEX TIMES
The drugmaker posted second-quarter revenue of $15 billion and adjusted diluted earnings per share of $0.77, saying both figures beat its own forecast levels.
THE APEX TIMES
Shares of Eli Lilly (LLY) jumped more than 5% in premarket trading after the company lifted its annual revenue guidance, citing demand for its weight-loss and diabetes therapies.
THE APEX TIMES
Reported Q2 revenue strength from weight-loss and diabetes drugs helped Eli Lilly beat Wall Street expectations, with Mounjaro sales rising 91% year over year to $9.9 billion and Zepbound reaching $4.9 billion.
THE APEX TIMES
CVS Health reported a second-quarter earnings beat and raised its full-year profit forecast to as much as $8.10 per share, while market coverage also pointed to an Eli Lilly weight-loss drug arrangement as investors looked for demand and affordability outlines in obesity care.
THE APEX TIMES
A summary of Moderna, Inc.’s second-quarter 2026 earnings call circulated on a market-news feed on Aug. 1, yet the underlying figures and guidance details are not included in the information currently available for review.
THE APEX TIMES
Eli Lilly reported strong year-over-year revenue growth in the second quarter of 2026 and said its full-year guidance now slightly exceeds market expectations, following a period of accelerating demand for its key therapies.
THE APEX TIMES
CVS Health reported year-over-year sales growth of 7.3% in Q2 CY2026, topping market revenue expectations, and posted non-GAAP earnings of $2.58 per share, according to a report cited by Yahoo Finance.
THE APEX TIMES
The partnership expands Onsera’s injection-free weight and cardiometabolic treatment options by incorporating Eli Lilly’s FDA-approved oral GLP-1 therapy, Foundayo (orforglipron).
